TRIPs-Plus Treaties and Strengthening Protection of Pharmaceutical Inventions

Authors

  • Asadlou, Morteza Islamic Azad University, Tabriz Branch, Tabriz, Iran. (Corresponding author)
Abstract:

After concluding TRIPs agreement, the sphere of negotiation in respect of protecting new kinds of intellectual property rights especially pharmaceutical inventions transferred to bilateral and regional arrangements. TRIPs agreement has some flexibility to attract all countries. Industrialized countries believed that multilateral agreements protections based especially in regard of pharmaceutical inventions are not fairly enough and because of this, they are searching new stage to negotiate and apply their views. This evolution occurred in pursuance of industrialized countries endeavors to protect their national’s intellectual property rights abroad. In recent years industrialized countries began to negotiate bilateral agreements with their trading partners. Some of these agreements are concluding in trade and investment field but also contain important provisions about intellectual property rights including pharmaceutical inventions, while others directly aim at intellectual property rights. Standards of these treaties prevail those of multilateral agreements such as TRIPs and because of this, these treaties are known as TRIPs-plus treaties. Industrialized countries in TRIPs-plus protection from pharmaceutical inventions focus on several points in their bilateral and regional negotiations such as identifying new types of intellectual property rights, taking TRIPs-plus standards in intellectual property protection and setting limits on existing flexibilities in TRIPs agreement. In this article we study the concept and scope of TRIPs-plus rules in the realm of pharmaceutical inventions. We will also show that standards of these types of treaties go further than those of multilateral intellectual property treaties such as TRIPs. Please cite this article as: Jafarzadeh M, Asadlou M. TRIPs-Plus Treaties and Strengthening Protection of Pharmaceutical Inventions. Iran J Med Law 2020; 14(53): 233-257.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Patent law protection of inventions in medicine and pharmaceutical industry.

Simply saying, inventions represent new solutions to technical problems. The word “technique” means “restraining of natural forces and controlled use of natural phenomena” , that is “human activity in the field of material phenomena characterized by space, time, matter and energy” . Thus, the technique is, actually, human activity to master and control nature. Once the domain of technique was c...

full text

the protection of pharmaceutical inventions and human rights challenges

although intellectual property rights (iprs) in this era specially after the constitution of world trade organization (wto) have been concerned from economic and commercialization point of view, human rights perspective to iprs has been increased and so, human rights groups have highlighted certain challenges between iprs and human rights, have tried to adjust economic perspective and have soug...

full text

trips: patenting of biotechnological inventions

granting of intellectual property rights on biological materials could be very contentious issue from cultural, legal, ethical and religious points of view. this could be even more complicated, once it acquires an international dimension. the agreement on trade related intellectual property rights (trips) is the latest international arrangement under which, a complex structure for international...

full text

AIDS and TRIPS Pharmaceutical Patents, Generic Drugs and Public Health Under The TRIPS Agreement

The signing of the TRIPS agreement in 1994 heralded the world-wide enforcement of the type of intellectual property rights regime that had been established in the most developed countries. The arrival of this type of regime, which provides enlarged and powerful protection to patent-holders, coincided with the global development of the AIDS epidemic. This generated a series of new problems, part...

full text

From TRIPS to “TRIPS Plus” provisions. Patents protection and public health promotion in developing countries: raising the stakes for drugs accessibility

According to the latest UNAIDS estimation (2008), about 33.2 million people are living with HIV/AIDS in the world in 2007, mostly in developing countries. More than 2.5 million people were newly infected this year and 2.1 million people died of AIDS. Due to prevention programme and changes in behaviour, the epidemic seems to peak in the 90s. Yet, the Sub-Saharan region still bears the largest b...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 14  issue 53

pages  233- 257

publication date 2020-06

By following a journal you will be notified via email when a new issue of this journal is published.

Keywords

No Keywords

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023